Weight-loss drug reduces risk of early death for patients with heart failure, trial finds

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals.

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals.

Read more https://www.sciencedaily.com/releases/2024/11/241120193142.htm